

## RESEARCH PAPER

RANTES stimulates  $\text{Ca}^{2+}$  mobilization and inositol trisphosphate ( $\text{IP}_3$ ) formation in cells transfected with G protein-coupled receptor 75A Ignatov<sup>1</sup>, J Robert<sup>2</sup>, C Gregory-Evans<sup>3</sup> and HC Schaller<sup>1</sup><sup>1</sup>Zentrum für Molekulare Neurobiologie Hamburg, Universität Hamburg, Hamburg, Germany; <sup>2</sup>Département d'Endocrinologie, Institut Cochin, Université René Descartes, Paris, France and <sup>3</sup>School of Medicine, Department of Visual Neuroscience, Imperial College London, London, UK

**Background and purpose:** RANTES is an inflammatory chemokine with a critical role in T-lymphocyte activation and proliferation. Its effects are mediated through G protein-coupled heptahelical receptors (GPCRs). We show for the first time that RANTES activates the orphan G protein-coupled receptor 75 (GPR75).

**Experimental approach:** To identify a ligand for GPR75 we have used three different and independent methods, namely luciferase assay, bioluminescence assay and  $\text{IP}_3$  accumulation assay.

**Key results:** Treatment of cells expressing GPR75 with subnanomolar concentrations of RANTES led to stimulation of the luciferase activity in a reporter-gene assay, an increase in inositol trisphosphate, and intracellular  $\text{Ca}^{2+}$ . The latter effect was blocked by the phospholipase-C inhibitor (PLC) U73122 indicating that Gq proteins mediate GPR75 signaling. RANTES enhanced the phosphorylation of AKT and mitogen-activated protein kinase (MAPK) in GPR75-transfected cells and this effect was blocked by the PLC inhibitor U73122 and the phosphatidylinositol 3-kinase (PI3K) inhibitor, wortmannin. The hippocampal cell line HT22, which expresses GPR75 endogenously, but not the other known RANTES receptors, was used to study the effects of RANTES and GPR75 on neuronal survival. Treatment of HT22 cells with RANTES significantly reduced the neurotoxicity of amyloid- $\beta$  peptides, by activating PLC and PI3K.

**Conclusions and implications:** This demonstrate clearly and undoubtedly the ability of RANTES to act on GPR75. Defects in the RANTES/GPR75-signaling pathway may contribute to neuroinflammatory and neurodegenerative processes as observed in Alzheimer's disease.

British Journal of Pharmacology (2006) 149, 490–497. doi:10.1038/sj.bjp.0706909; published online 25 September 2006

**Keywords:** RANTES; GPCR; GPR75; chemokine; HT22 cells

**Abbreviations:**  $\text{A}\beta$ , amyloid- $\beta$ ; CRE, cAMP-response element; CV-1, African green monkey kidney cells; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GPCRs, G protein-coupled receptors; GPR75, G protein-coupled receptor 75; HEK293, human embryonic kidney cells;  $\text{IP}_3$ , inositol trisphosphate; MAPK, mitogen-activated protein kinase; MCP3, monocyte chemoattractant protein 3; MIP1 $\alpha$ , macrophage inflammatory protein 1 $\alpha$ ; MIP1 $\beta$ , macrophage inflammatory protein 1 $\beta$ ; MRE, multiple-response element; PI3K, phosphatidylinositol 3-kinase; PLC, phospholipase-C; PTX, pertussis toxin; RANTES, regulated upon activation, normal T-cell expressed and secreted; SDF-1, stromal cell-derived factor-1; SRE, serum-response element

## Introduction

G protein-coupled receptors (GPCRs) are the largest family of cell-surface receptors encoded by more than 1000 genes in the human genome (Howard *et al.*, 2001). They regulate numerous physiological and pathophysiological processes in response to extracellular stimuli, for example, hormones, peptides, neuroamines, growth factors, lipids, ions and

sensory signals. Identification of novel GPCRs and their endogenous ligands can help to gain insight into different physiological processes and pathophysiological disorders (Howard *et al.*, 2001).

Recently, G protein-coupled receptor 75 (GPR75) was identified as a novel human GPCR: the corresponding gene maps to human chromosome 2p16 and encodes a 546 amino-acids protein (Tarttelin *et al.*, 1999). The entire open-reading frame is present within a single exon, a typical hallmark of GPCRs. Human GPR75 is most closely related to a putative *Caenorhabditis elegans* neuropeptide Y receptor

Correspondence: Dr A Ignatov, Universitätsfrauenklinik, Medizinische Fakultät, Otto-von-Guericke-Universität, Magdeburg, Germany.  
E-mail: atanas.ignatov@medizin.uni-magdeburg.de  
Received 22 May 2006; revised 14 July 2006; accepted 18 August 2006; published online 25 September 2006

(24% homology), the rat galanin receptor type 3 (25% homology) and the porcine growth hormone secretagogue receptor type 1b (25% homology) (Tarttelin *et al.*, 1999). This suggests that peptides could be cognate ligands for GPR75.

It has been reported that human GPR75 is predominantly expressed in the retina and in the central nervous system (CNS) (Tarttelin *et al.*, 1999; Sauer *et al.*, 2001). Interestingly, an inherited retinal dystrophy, Doyen's honeycomb retinal dystrophy, colocalizes with GPR75 on chromosome 2p16 (Tarttelin *et al.*, 1999). However, no link between GPR75 and the disease pathology has been found (Tarttelin *et al.*, 1999). Similarly, no direct connection was evident for another retina-associated disease, age-related macular degeneration (Sauer *et al.*, 2001). Further functional studies and identification of the endogenous ligand are required to understand the role of GPR75 in retinal and brain physiology and pathophysiology.

GPCRs serve as receptors for a large family of cytokines called chemokines that play a regulatory role in the inflammatory processes (Cartier *et al.*, 2005). RANTES (regulated upon activation, normal T-cell expressed and secreted), a 68 amino-acid protein, belongs to the CC-chemokine subfamily (it has the systematic name CCL 5), and was originally identified as a T-cell-specific gene (Schall *et al.*, 1988). In addition to its well-established role in the immune system, recent data suggest its involvement in CNS homeostasis, brain inflammation, and ocular and neurodegenerative diseases (Mennicken *et al.*, 1999; Wallece *et al.*, 2004; Cartier *et al.*, 2005).

Here, we report the identification and cloning of a mouse ortholog of the human GPR75 expressed predominantly in mouse brain and heart. In a search for ligands for this receptor, we discovered that RANTES increased inositol trisphosphate (IP<sub>3</sub>) and intracellular Ca<sup>2+</sup> in cells heterogeneously expressing GPR75. It responded via Gq protein-coupled signal-transduction pathways and activated phospholipase-C (PLC). RANTES via GPR75 led to the activation of the antiapoptotic mitogen-activated protein kinase (MAPK) via the PLC/phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway and prevented amyloid- $\beta$  (A $\beta$ )-induced cell death in the hippocampal cell line, HT22.

## Methods

### Cells

The human embryonic kidney (HEK), African green monkey kidney (CV-1) and hippocampal (HT22) cell lines were kindly provided by Dr Axel Methner (ZMNH, Hamburg, Germany) and the Chinese hamster ovary (CHO-K1) cells by Dr Jenny Stables (GlaxoSmithKline, Stevenage, UK).

### Amplification and cloning of GPR75

Human GPR75 was amplified by polymerase chain reaction (PCR) from human genomic DNA using 5'-CATATGGATC CACGGTGGGGACTGGAA-3' as forward and 5'-ATCTAAA GCTTATGAACTCAACAGGCCA-3' as reverse primers. The GPR75-PCR product was inserted into the pGEM-T-easy vector (Promega, Heidelberg, Germany) and subcloned into

the *Bam*HII/*Hind*III sites of the pEGFPN1 vector, bearing the enhanced green fluorescent protein (EGFP) (Promega). A query in the mouse genomic database with the human GPR75 sequence revealed a mouse ortholog of GPR75. A 1623 bp fragment covering the entire open-reading frame of mouse GPR75 was amplified by PCR from the genomic mouse DNA using the primer set 5'-ATGAACACAAGTG CCCCCTTCAGATGTCC-3' and 5'-TTAAACAGAGGGGATA GGAATTTGTTTT-3'. The resulting full-length nucleotide sequence of mouse GPR75 was submitted to GenBank (accession number AY253852). The GPR75-PCR product was inserted into the pGEM-T-easy vector (Promega). The correctness of all constructs was verified by sequencing.

### Tissue distribution of GPR75 and amplification of CCR1, CCR3 and CCR5 in HT22 cells

A mouse multiple-tissue cDNA panel (Clontech, Heidelberg, Germany) and cDNA from HT22 cells were probed by PCR with the above described mouse-specific forward primer for GPR75. The reverse primer matched the 819–843 nucleotide sequence of AY253852. Analysis of the transcript distribution of CCR1, CCR3 and CCR5 in HT22 cells was performed by amplification of the fragments with following gene-specific primers: for CCR1, a 834 bp fragment was amplified with primers derived from positions 1–25 and 811–834 from the mouse sequence (GenBank accession number U29678); for CCR3, a 798 bp fragment ranged from positions 56–78 to 830–854 of the mouse sequence (GenBank accession number U29677); for CCR5, a 813 bp fragment spanned positions 240–136 and 1031–1053 of the human sequence (GenBank accession number X91492). As templates served cDNAs from mouse HT22 cells was used as a template. Amplification of the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) fragment served as a control.

### Luciferase reporter-gene assay

CV-1 cells were plated in 96-well white, clear-bottom plates in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen, Karlsruhe, Germany) supplemented with 10% fetal calf serum (FCS) and antibiotics. After 24 h, the cells were transiently transfected with human GPR75 or vector cDNA (as control) and the reporter-gene construct using lipofectamine 2000 (Invitrogen). The reporter contains three multiple-response elements (MREs), a cAMP-response element (CRE) and a serum-response element (SRE) upstream of the luciferase gene (Jiang *et al.*, 2003). The ratio of the receptor or vector to the reporter-gene construct was 4:1. The cells were incubated at 37°C in serum-free OptiMEM 1 (Invitrogen) containing the DNA-lipofectamin 2000 complex. After 4–6 h, the medium was replaced by DMEM, supplemented with 5% FCS and incubated for additional 24 h, followed by incubation for 24 h in a serum-free defined medium supplemented with 5  $\mu$ g ml<sup>-1</sup> insulin, 30  $\mu$ g ml<sup>-1</sup> transferrin, 20  $\mu$ M ethanolamine, 30 nM sodium selenite, 1  $\mu$ M sodium pyruvate, 1% non-essential amino acids and 2 mM glutamine in DMEM. Thereafter, the cells were additionally incubated for 5 h at 37°C with various ligands at different concentrations, in the presence or absence of 5  $\mu$ M forskolin, dissolved in 50  $\mu$ l

serum-free defined medium. To determine the luciferase activity, 25  $\mu$ l Bright-Glo (Promega) was added, and after 2 min the luminescence signal was measured at 37°C using a TriLux luminescence counter (Perkin-Elmer Life Sciences, Rodgau, Germany).

#### *Aequorin-based bioluminescence assay*

The assay was performed as already described (Ignatov *et al.*, 2003). Briefly, CHO-K1 cells were transiently transfected with GPR75 or vector cDNA together with a construct encoding the mitochondrially targeted aequorin as  $\text{Ca}^{2+}$  sensor. The cells were seeded in 96-well plates for 24 h, followed by incubation at 37°C in a serum-free OptiMEM 1 medium containing the DNA-lipofectamin 2000 complex. After 4–6 h, the medium was replaced by DMEM-F12, supplemented with 5% FCS and incubated for 24 h, followed by 24 h incubation in serum-free defined medium. To measure the  $\text{Ca}^{2+}$ -induced luminescence, cells were treated for 4 h with 5  $\mu$ M coelenterazine as cofactor for aequorin. Ligands were dissolved in serum-free defined medium, added to the cells and the luminescence was read at a luminometer (Berthold Technologies) at 37°C for 15 s.

#### *IP<sub>3</sub> determination*

Human embryonic kidney (HEK293) cells were grown in DMEM supplemented with 7.5% FCS, 0.5 mM glutamine, 100 IU ml<sup>-1</sup> penicillin and 100  $\mu$ g ml<sup>-1</sup> streptomycin. To measure IP<sub>3</sub> production, HEK293 cells were transiently transfected using the Effecten reagent (Qiagen, Courtaboeuf, France) according to the manufacturer's instructions and grown in 24-well plates. The cells were metabolically labeled for 24 h with 4  $\mu$ Ci ml<sup>-1</sup> of myo-[<sup>3</sup>H]inositol (Amersham Biosciences, Freiburg, Germany). They were stimulated for 30 min with various concentrations of chemokines in the presence of 10 mM LiCl. IP<sub>3</sub> content was determined by scintillation counting after methanol extraction, separation on a Dowex AG1-X8 column (Bio-Rad, Marnes-La-Coquette, France) and elution with 1 M ammonium formate, as described previously (Robert *et al.*, 2005).

#### *Phosphorylation of Akt and MAPK*

CV-1 cells, transfected with vector or GPR75, were grown in six-well plates overnight, then incubated with 1 nM RANTES for 0, 1, 5, 10 and 15 min with or without prior incubation with various inhibitors. The cells were washed with phosphate-buffered saline, collected in buffer preheated to 95°C (5 mM Na<sub>2</sub>HPO<sub>4</sub>, 2% sodium dodecyl sulfate, 0.1 M dithiothreitol, 5% beta-mercaptoethanol, 10% glycerol and 0.05% bromophenol blue) and incubated for 5 min at 95°C. The cells were ultrasonicated and the proteins in the homogenates separated by polyacrylamide gel electrophoresis. After semidry blotting, the membranes were immunodetected with monoclonal antibodies against phosphorylated MAPK (1:2000) or phosphorylated Akt kinase (1:2000). Following incubation with anti-mouse or anti-rabbit horseradish peroxidase-conjugated secondary antibodies (1:2000) (New England Biolabs, Frankfurt, Germany), the detection

was accomplished with the SuperSignal peroxidase substrate (Perbio Science, Bonn, Germany). The same membranes were stripped and reprobed with a polyclonal antibody against total MAPK (1:1000) (New England Biolabs) and with a monoclonal antibody against acetylated tubulin (1:1000) (Sigma-Aldrich, Taufkirchen, Germany).

#### *MTT viability assay*

HT22 cells, transfected with GPR75 or vector alone, were grown in 96-well plates for 24 h. Cells were pretreated with 1 nM of different chemokines for 1 h, before addition of 20  $\mu$ M A $\beta$ <sub>1–42</sub>, A $\beta$ <sub>25–35</sub>, or as control the A $\beta$  peptide with a reverse amino-acid sequence A $\beta$ <sub>42–1</sub>. A $\beta$  peptides were dissolved in 0.1 N HCl to obtain a 1 mM stock solution, briefly heated to 95°C, neutralized with NaOH, and aliquots were stored frozen until use. The cells were incubated for 24 h with the A $\beta$  peptides before treatment for 2 h in the dark at 37°C with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). Following incubation with a lysis buffer, the cell viability was determined by measuring the absorbance at 560 nm.

#### *Data analysis*

The results are expressed as means of six determinations  $\pm$  s.d. Statistical analysis was carried out using Student's *t*-test for paired observations. When three or more means were compared, analysis of variance was applied using the Prism program (Graph Pad Software, San Diego, CA, USA). Curve fittings were performed with the Prism program.

#### *Ligands and signal-transduction inhibitors*


RANTES (CCL 5), macrophage inflammatory protein 1 $\alpha$  (MIP1 $\alpha$ ; CCL 3), macrophage inflammatory protein 1 $\beta$  (MIP1 $\beta$ ; CCL 4), monocyte chemoattractant protein 3 (MCP3; CCL 7), stromal cell-derived factor-1 (SDF-1; CXCL 12) and A $\beta$  peptides were obtained from Bachem (Weil am Rhein, Germany), U73122 from Merck (Darmstadt, Germany) and SDF-1, wortmannin and PTX from Sigma-Aldrich. Stock solutions were prepared as recommended by the manufacturers and were stored at –20°C.

## Results





#### *Cloning and tissue-expression profile of mouse GPR75*

Comparison of the nucleotide sequence of the intron less human GPR75 with the mouse genomic database allowed construction of the PCR primers and amplification of mouse GPR75. Sequence analysis revealed an open-reading frame of 1623 nucleotides corresponding to a protein of 540 amino acids (GenBank accession number AY253852). It shared 87% identity at the amino-acid level with human GPR75. Mouse GPR75 was found to map to chromosome 11A4. Tissue distribution of mouse GPR75 was analyzed by PCR on a cDNA panel representing 12 different tissues from adult mouse and from whole mouse embryos (Figure 1). The highest level of expression was observed in the brain and

heart. Lower levels of GPR75 expression were detected in skeletal muscles and in 7- and 15-day-old embryos. Very low abundance of expression was observed in the liver, kidney and 17-day-old embryo.



**Figure 1** Expression analysis of mouse GPR75 mRNA. The expression of GPR75 mRNA in different adult mouse tissues and 7-, 11-, 15- and 17-day-old embryos was assessed by PCR using a multiple-tissue cDNA panel and GPR75-specific primers that amplify a product of 843 bp (upper panel). GAPDH served as loading control (bottom panel).



**Figure 2** GPR75-mediated stimulation of luciferase expression by RANTES. CV-1 cells were transiently transfected with either GPR75 or empty vector (Mock) and the MRE/SRE/CRE-reporter construct. 48 h later, cells were stimulated for 5 h with different concentrations of RANTES in the absence (a), or presence (b) of 5  $\mu$ M forskolin. The luciferase activity is expressed in relative light units (RLU). (c) The stimulation of the luciferase activity given as a ratio between the luminescence measured for the individual samples in RLU and the maximal stimulation (RLU max). The calculated  $EC_{50}$  values were: 0.11 and 0.16 nM. (d) Cells were stimulated for 5 h with 5  $\mu$ M forskolin and with various concentrations of different chemokines. Note that in addition to RANTES, only MIP1 $\alpha$  increased the luciferase activity over the forskolin-stimulated background response with an  $EC_{50}$  value of 1 nM. Data are expressed as mean values  $\pm$  s.d.

*RANTES and MIP1 $\alpha$  stimulate the luciferase activity in a reporter-gene assay via GPR75*

To identify the endogenous ligand(s) for different GPCRs, a variety of peptides and peptide-enriched tissue extracts were tested in a luciferase-reporter assay (Jiang *et al.*, 2003). For this purpose CV-1 cells were co-transfected with plasmids bearing the GPCR of interest and the luciferase reporter gene. As control served an empty vector or another GPCRs. Stimulation of GPCRs with a cognate ligand should result in an increase (Gs, Gq) or a decrease (Gi) of the forskolin-induced luminescence signals (Jiang *et al.*, 2003). The transfection efficiency of CV-1 cells, transiently expressing GPR75 was in the range of 25–30% as assessed by GPR75-EGFP fluorescence. We found that RANTES increased the basal luciferase activity (Figure 2a) as well as the forskolin-induced luciferase activity (Figure 2b) in cells transiently transfected with the GPR75, suggesting a coupling of GPR75 to Gq- or Gs-proteins. No response to RANTES was observed in cells transfected with the EGFP vector alone (Figures 2a and b). The comparison of the dose–response curves, obtained by using the ratio between the luminescence of

the individual samples and by maximal stimulation, revealed quite similar half-maximal effective concentrations ( $EC_{50}$ ) of 0.11 and 0.26 nM in the presence and absence of forskolin, respectively (Figure 2c). A typical hallmark of the chemokine receptors is their promiscuity (Cartier *et al.*, 2005), therefore other peptides belonging to CC- and CXC-chemokine subfamily were also tested for their effect on the luciferase activity in GPR75-transfected cells. In addition to RANTES, only MIP1 $\alpha$  reacted with GPR75 (Figure 2d), albeit with lower affinity ( $EC_{50}$  = 1 nM). MIP1 $\beta$ , MCP3 and SDF-1 had no effect on the stimulation of the luciferase activity (Figure 2d).

#### RANTES stimulates $Ca^{2+}$ mobilization in CHO-K1 cells expressing GPR75

The luciferase activity can be increased both over Gq- or Gs-dependent pathways (Jiang *et al.*, 2003). With the next set of experiments, we aimed to determine the natural coupling of the GPR75 receptor to intracellular signaling pathways. CHO cells were transiently co-transfected with constructs coding for GPR75 or vector and with the bioluminescent  $Ca^{2+}$  sensor apoaequorin. This assay had proven to be useful for ligand identification as described earlier (Ignatov *et al.*, 2003). GPR75 transfection efficiencies were in the range of 30–40%. RANTES was able to stimulate  $Ca^{2+}$ -induced bioluminescence response in GPR75-transfected cells, but not in vector-transfected cells (Figure 3a). No effect was observed after activation with other chemokines including MIP1 $\alpha$ . The RANTES-induced  $Ca^{2+}$  mobilization was dose dependent, and the dose–response curve revealed an  $EC_{50}$  of 0.12 nM (Figure 3a). It indicates that GPR75 utilizes endogenous G proteins to stimulate PLC.


Moreover, the RANTES-induced bioluminescence in GPR75-transfected cells was completely blocked by preincubation of the cells with the PLC-specific inhibitor, U73122, whereas PTX did not show a significant reduction (Figure 3b).

#### GPR75 induces $IP_3$ formation in HEK293 cells

To confirm the Gq-protein coupling of GPR75, we measured the production of  $IP_3$  in GPR75-transfected HEK293 cells after stimulation with various concentrations of different chemokines. RANTES enhanced  $IP_3$  formation in GPR75-transfected cells in a dose-dependent manner with an  $EC_{50}$  value of 0.3 nM (Figure 4), which was in the same order of magnitude as the values obtained in the luciferase-reporter and the aequorin-based bioluminescence assays. Activation with MIP1 $\alpha$ , MIP1 $\beta$ , MIP3 and SDF-1 led to no detectable change in the  $IP_3$  production.


#### RANTES activates phosphorylation of Akt and MAPK in GPR75-transfected CV-1 cells

Activation of Akt and MAPK is crucial for promoting cell proliferation and cell survival, both typical chemokine-induced processes (Cartier *et al.*, 2005). To determine if this is the case, we investigated the influence of GPR75 and RANTES on the activation of Akt and MAPK. CV-1 cells



**Figure 3** RANTES stimulates the  $Ca^{2+}$ -induced bioluminescence in GPR75-transfected CHO-K1 cells. (a) CHO-K1 cells were transiently co-transfected with GPR75 or empty vector and apoaequorin as  $Ca^{2+}$  sensor. Cells were treated with different concentrations of RANTES, and the  $Ca^{2+}$ -induced bioluminescence was measured at 469 nm and is expressed as RLU/RLU max. The dose–response curve yielded an  $EC_{50}$  value of 0.12 nM. (b) CHO-K1 cells transiently co-transfected with apoaequorin and GPR75 or empty vector were pretreated with 50 ng ml $^{-1}$  PTX for 18 h, with 5  $\mu$ M PLC inhibitor U73122 for 10 min, before the response to RANTES was measured as  $Ca^{2+}$ -induced luminescence. The RANTES-induced  $Ca^{2+}$  increase was significantly inhibited by U73122 compared to untreated controls, whereas PTX had no effect ( $***P < 0.001$ ). Data are expressed as mean values  $\pm$  s.d.

transiently transfected with either GPR75 or empty vector were incubated with 1 nM RANTES at various times. The phosphorylation of Akt and MAPK was detected using specific antibodies for phosphorylated Akt and phosphorylated p44/p42 MAPK. RANTES induced a sustained phosphorylation of Akt and MAPK in GPR75-transfected cells (Figure 5a), but not in vector-transfected cells (data not shown). The phosphorylation of Akt was evident after 5 min, whereas the MAPK phosphorylation required 10 min. The levels of total MAPK and tubulin remained constant (Figure 5a). To identify the signaling pathway involved in the RANTES-induced Akt and MAPK phosphorylation, we preincubated the CV-1 cells transiently transfected with




**Figure 4** RANTES stimulates IP<sub>3</sub> formation in GPR75-transfected HEK293 cells. HEK293 cells were transiently transfected with GPR75. Cells were treated with various concentrations of RANTES, MIP1 $\alpha$ , MIP1 $\beta$ , MCP3 and SDF-1 for 30 min, and the production of IP<sub>3</sub> was measured in extracts from intact HEK293 cells. The dose-response curve yielded an EC<sub>50</sub> value of 0.3 nM for RANTES-induced production of IP<sub>3</sub>. Data are expressed as mean values  $\pm$  s.d.

GPR75, with wortmannin, U73122 and PTX, before addition of RANTES. Wortmannin and U73122 abolished the RANTES-induced phosphorylation of Akt and MAPK, whereas PTX had no effect (Figure 5b).

*GPR75 mediates the RANTES-induced neuroprotection against A $\beta$  toxicity*

The hippocampus is a primary target for neuronal degeneration in patients with Alzheimer's disease. GPR75 has been found to be expressed in this region (Tarttelin *et al.*, 1999; Sauer *et al.*, 2001). We next asked, whether RANTES and GPR75 can influence the A $\beta$ -induced cell death in the mouse hippocampal cell line HT22 with endogenous GPR75 (Figure 6). Approximately 60% of HT22 cells died 24 h after A $\beta$ <sub>1-42</sub> exposure (Figure 6). Comparable results were obtained with A $\beta$ <sub>25-35</sub>, which has been shown to be as neurotoxic as full-length A $\beta$ <sub>1-42</sub> (Varadarajan *et al.*, 2001). The A $\beta$  peptide with a reverse amino-acid sequence (A $\beta$ <sub>42-1</sub>) had no effect (Figure 6). Pretreatment of the cells with RANTES before the exposure to 20  $\mu$ M A $\beta$ <sub>25-35</sub> led to a significant increase in cell viability compared to the untreated cells (Figure 7a). Phase-contrast microscopy confirmed the prevention of cell death by preincubation with RANTES (compare Figures 7b and c). Dying cells were characterized by condensed cell bodies and retracted cellular protrusions (Figure 7b). Additionally, transient transfection with GPR75 stabilized the HT22 cells and further increased their survival efficiency (Figure 7a). Interestingly, wortmannin and U73122 completely abrogated the RANTES-induced survival effect (Figure 7a). In addition to RANTES, only MIP1 $\alpha$  inhibited the A $\beta$  toxicity, albeit with a lower efficiency (Figure 7d). As observed with RANTES, MIP1 $\alpha$ -stimulated protection was abolished by wortmannin and U73122.

Next, to determine the specificity of the GPR75 effect, we analyzed the abundance of the other three known RANTES




**Figure 5** RANTES induces the phosphorylation of Akt and MAPK in GPR75-transfected CV-1 cells via the PLC/PI3K/Akt signaling pathway. (a) CV-1 cells were transiently transfected with GPR75 and 48 h later incubated with 1 nM RANTES for the indicated times. Whole-cell extracts were analyzed by Western blotting using antibodies against phosphorylated MAPK (pMAPK), phosphorylated Akt (pAkt), total MAPK (tMAPK) and acetylated tubulin. Note that the levels of total MAPK and tubulin remained constant. The blot is a representative of three different experiments. (b) GPR75-transfected CV-1 cells were pretreated with 50 ng ml<sup>-1</sup> PTX for 18 h, with 5  $\mu$ M PLC inhibitor U73122 for 10 min, and with 0.5  $\mu$ M PI3K inhibitor wortmannin for 1 h, before 1 nM RANTES was added for 10 min. The blot is representative of two experiments.

receptors in HT22 cells using PCR. GPR75 message was readily amplified by 30 cycles (Figure 6a), whereas the amplification of CCR1, CCR3 and CCR5 failed even after 60 cycles.

**Discussion**


GPR75 contains most of the characteristic features of GPCRs, namely seven transmembrane spanning domains, N-glycosylation sites in the N-terminus, and numerous serine and threonine phosphorylation sites in the C-terminus. Comparison of amino sequence, however, showed less than 25% homology to other GPCRs. Among various peptides and peptide-enriched extracts we tested, only the chemokine RANTES (CCL 5) turned out to stimulate the orphan GPR75. RANTES treatment of cells expressing GPR75 heterologously led to an increase in luciferase activity in a reporter-gene assay and stimulated Ca<sup>2+</sup> mobilization and IP<sub>3</sub> formation in respective assays with EC<sub>50</sub> values in subnanomolar range. So far 19 chemokine receptors have been identified (Cartier *et al.*, 2005). They share about 30–50% sequence homology,

show common structural features and can be activated by multiple chemokines (Cartier *et al.*, 2005). From the whole spectrum of chemokines tested with GPR75, only MIP $\alpha$  stimulated the luciferase activity, albeit with lower efficacy ( $EC_{50} = 1$  nM) compared to RANTES. GPR75 possesses neither homology to the chemokine-receptor family nor promiscuity regarding ligands, which distinguish it as a new type of chemokine receptor.




**Figure 6** A $\beta$  peptides reduce cell viability in HT22 cells. (a) HT22 cells express GPR75 endogenously but not CCR1, CCR3 and CCR5 chemokine receptors (upper panel). GAPDH served as a loading control (lower panel). cDNA represents the negative control. The experiment is representative of three detections. (b) HT22 cells respond to a 24 h treatment with A $\beta$  peptides by cell death, as assessed by the MTT assay. Note that no difference was observed between 20  $\mu$ M A $\beta_{1-42}$  and A $\beta_{25-35}$ , whereas A $\beta_{42-1}$  had no effect. Data are expressed as mean values  $\pm$  s.d.

RANTES is expressed in various normal and diseased tissues, for example, skeletal muscle, myocytes, kidney, retina and brain (Crane *et al.*, 1998; Bajetto *et al.*, 2001; Hirata *et al.*, 2003; Wallece *et al.*, 2004). The highest expression of human GPR75 has been detected in CNS (Tarttelin *et al.*, 1999; Sauer *et al.*, 2001), whereas our results show that the mouse GPR75 is present in cDNA from adult mouse brain, heart, skeletal muscle, kidney and in cDNA from 7- and 11-day-old mouse embryos (Figure 1). This expression pattern overlaps partially with the expression of RANTES. Therefore, it is tempting to speculate that RANTES



**Figure 7** RANTES protects HT22 cells from cell death induced by A $\beta$  peptide. (a) HT22 cells were preincubated for 1 h with and without 1 nM RANTES (R), before addition of 20  $\mu$ M A $\beta_{1-42}$  (A $\beta$ ). After 24 h, cell viability was determined using the MTT assay. The effect of RANTES on cell survival was significant compared to cells treated with A $\beta$  alone ( $*P < 0.05$ ). Additional transient transfection with GPR75 increased the protective effect of RANTES ( $**P < 0.01$ ). The protective effect of RANTES was significantly inhibited by pretreatment of HT22 cells for 1 h with 0.5  $\mu$ M wortmannin (W) or for 10 min with 5  $\mu$ M U73122 (U), before RANTES was added ( $*P < 0.05$ ). (b and c) HT22 cells were seeded in six-well plates for 24 h. They were incubated for 24 h with 20  $\mu$ M A $\beta_{1-42}$  without (b) or with (c) preincubation with 1 nM RANTES for 1 h and visualized by phase-contrast microscopy. Scale bar = 50  $\mu$ m. (d) After pretreatment for 1 h with 1 nM of the indicated chemokines, HT22 cells were incubated with 20  $\mu$ M A $\beta_{25-35}$ , and after 24 h the cell viability was determined by the MTT assay. Only RANTES and, to a lesser extent, MIP1 $\alpha$  had a significant neuroprotective effect ( $**P < 0.01$  and  $*P < 0.05$ , respectively). The data in (a) and (d) are expressed as mean values  $\pm$  s.d.



and GPR75 may play an important role in the physiology and pathophysiology of these tissues. The expression of GPR75 in the developing embryo is suggestive of an essential role for organogenesis. However, a more detailed study by *in situ* hybridization and using knockout strains is needed to assess the function of GPR75 signaling in multiple embryonic events.

The hippocampus is one of the areas affected in patients with Alzheimer's disease, where the histopathology is manifested by aggregation of the A $\beta$  peptide and recruiting of several other cellular proteins (Cummings *et al.*, 1998). The role of chemokines in the etiology and pathophysiology of Alzheimer's disease is not well understood. It has been proposed that A $\beta$  is able to stimulate chemokine production in astrocytes and oligodendrocytes and the accompanying neuroinflammatory effect induces neuronal cell death (Bajetto *et al.*, 2001; Cartier *et al.*, 2005). It was of particular interest to investigate a possible role of GPR75 in A $\beta$ -stimulated cell death. In the hippocampal cell line, HT22, which expresses GPR75 endogenously, RANTES reduced the cell death induced by A $\beta$ <sub>1–42</sub>. Transient transfection with GPR75 enhanced the neuroprotective effect of RANTES. Other chemokines – MIP1 $\beta$ , MCP3 – that activate the known RANTES receptors CCR1, CCR3 and CCR5 (Cartier *et al.*, 2005), were inactive, suggesting that the effects of RANTES are exclusively executed through the GPR75 in HT22 cells. It should be noted that the soluble form of A $\beta$  is less toxic than the aggregated form.

Akt and MAPK phosphorylation was stimulated by RANTES in CV-1 cells transfected with GPR75. The activation of Akt and MAPK is known to promote cell survival and growth (Marinissen and Gutkind 2001; Maceyka *et al.*, 2002; Li *et al.*, 2003), and may, therefore, explain the antiapoptotic action of RANTES on HT22 cells. A $\beta$ -induced cell death and the stimulation of Akt and MAPK phosphorylation were inhibited by wortmannin and U73122, suggesting a role for PI3K and PLC in the RANTES/GPR75-induced neuroprotection. Although RANTES increased the phosphorylation of both kinases with a similar pattern, with a maximal effect at 10 min, the fact that Akt phosphorylation preceded MAPK phosphorylation is indicative of a PI3K/Akt-coupled phosphorylation of MAPK.

In summary, we report the characterization of a new kind of chemokine receptor, GPR75. The chemokine RANTES was identified as cognate ligand for the GPR75 and it prevented A $\beta$ -induced cell death in the hippocampal cell line, HT22, via activation of the pro-survival signaling pathway PLC/PI3K/Akt/MAPK. This finding offers a unique approach for unraveling the molecular mechanisms of GPR75 and RANTES in brain physiology and pathophysiology and suggests a new potential target for limiting A $\beta$ -stimulated neuronal loss.

## Acknowledgements

We thank Dr Axel Methner for kindly providing the luciferase gene-reporter construct and Simon Hempel for help with the figures.

## Conflict of interest

The authors state no conflict of interest.

## References

- Bajetto A, Bonavia R, Barbero S, Florio T, Schettini G (2001). Chemokines and their receptors in the central nervous system. *Front Neuroendocrinol* 22: 147–184.
- Cartier L, Hartley O, Dubois-Dauphin M, Krause KH (2005). Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases. *Brain Res Brain Res Rev* 48: 16–42.
- Crane JJ, Kuppner MC, McKillop-Smith S, Knott RM, Forrester JV (1998). Cytokine regulation of RANTES production by human retinal pigment epithelial cells. *Cell Immunol* 184: 37–44.
- Cummings JL, Vinters HV, Cole GM, Khachaturian ZS (1998). Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities. *Neurology* 51: S2–S17 (Discussion S65–S17).
- Hirata A, Masuda S, Tamura T, Kai K, Ojima K, Fukase A *et al.* (2003). Expression profiling of cytokines and related genes in regenerating skeletal muscle after cardiotoxin injection: a role for osteopontin. *Am J Pathol* 163: 203–215.
- Howard AD, McAllister G, Feighner SD, Liu Q, Nargund RP, van der Ploeg LH *et al.* (2001). Orphan G protein-coupled receptors and natural ligand discovery. *Trends Pharmacol Sci* 22: 132–140.
- Ignatov A, Lintzel J, Hermans-Borgmeyer I, Kreienkamp HJ, Joost P, Thomsen S *et al.* (2003). Role of the G protein-coupled receptor GPR12 as high-affinity receptor for sphingosylphosphorylcholine and its expression and function in brain development. *J Neurosci* 23: 907–914.
- Jiang C, Chen G, Zeng X, Ouyang K, Hu Y (2003). Generation of a bioactive neuropeptide in a cell-free system. *Anal Biochem* 316: 34–40.
- Li Y, Gonzales I, Meinkoth JL, Fieeld J, Kazanietz MG, Li Y *et al.* (2003). Lysophosphatidic acid promotes survival and differentiation of rat Schwann cells. *J Biol Chem* 278: 9585–9591.
- Maceyka M, Payne SG, Milstein S, Spiegel S (2002). Sphingosine kinase, sphingosine-1-phosphate, and apoptosis. *Biochim Biophys Acta* 1585: 193–201.
- Marinissen MJ, Gutkind JS (2001). G-protein-coupled receptors and signaling networks: emerging paradigms. *Trends Pharmacol Sci* 22: 368–376.
- Mennicken F, Maki R, De Souza EB, Quirion R (1999). Chemokines and chemokine receptors in the CNS: a possible role in neuroinflammation and patterning. *Trends Pharmacol Sci* 20: 73–78.
- Robert J, Auzan C, Ventura MA, Clauser E (2005). Mechanisms of cell-surface rerouting of an ER-retained mutant of the vasopressin V1b/V3 receptor by a pharmacological chaperone. *J Biol Chem* 280: 42198–42206.
- Sauer CG, White K, Stohr H, Grimm T, Hutchinson A, Bernstein PS *et al.* (2001). Evaluation of the G protein coupled receptor-75 (GPR75) in age related macular degeneration. *Br J Ophthalmol* 85: 969–975.
- Schall TJ, Jongstra J, Dyer BJ, Jorgensen J, Clayberger C, Davis MM *et al.* (1988). A human T cell-specific molecule is a member of a new gene family. *J Immunol* 141: 1018–1025.
- Tarttelin EE, Kirshner LS, Bellingham J, Baffi J, Taymans SE, Gregory-Evans K *et al.* (1999). Cloning and characterization of a novel orphan G-protein-coupled receptor localized to human chromosome 2p16. *Biochem Biophys Res Commun* 260: 174–180.
- Varadarajan S, Kanaski J, Aksenova M, Lauderback C, Butterfield DA (2001). Different mechanisms of oxidative stress and neurotoxicity for Alzheimer's A beta (1–42) and A beta (25–35). *J Am Chem Soc* 123: 5625–5631.
- Wallece GR, Curnow S, Wloka K, Salmon M, Murray PI (2004). The role of chemokines and their receptors in ocular disease. *Prog Retin Eye Res* 23: 435–448.